Detecting Tumor DNA in Ovarian Cancer Patients
Author Information
Author(s): Hickey K P, Boyle K P, Jepps H M, Andrew A C, Buxton E J, Burns P A
Primary Institution: Leeds General Infirmary, University of Leeds
Hypothesis
Can tumor-specific genetic alterations be detected in the serum and peritoneal fluid of ovarian cancer patients?
Conclusion
Molecular detection methods can effectively identify tumor-specific alterations in ovarian cancer patients' serum and peritoneal fluid.
Supporting Evidence
- Tumour-specific abnormalities were detected in the serum of all but one of the stage Ia cases.
- Half of the occurrences of loss of heterozygosity identified in primary tumour material were detectable in the serum samples.
- Novel alleles indicative of microsatellite instability were found in 3/6 patients with stage Ia disease.
Takeaway
Doctors can find signs of cancer in the blood and fluid around the belly of women with ovarian cancer using special tests.
Methodology
DNA was extracted from serum and peritoneal fluid of ovarian cancer patients and analyzed for tumor-specific genetic alterations using six polymorphic microsatellite loci.
Limitations
The study had a small sample size and included only a limited number of genetic markers.
Participant Demographics
20 ovarian cancer patients, including six with stage Ia disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website